CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. CytomX Therapeutics, Inc. is not very popular among insiders. CytomX Therapeutics, Inc. is a mediocre stock to choose.

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of c...

News

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Ticker Report CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the stock, MarketBeat Ratings...\n more…

CytomX Therapeutics announces first patient dosed with CX-801

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY , in a Phase 1 Study in Patients with Solid Tumors

Globe Newswire SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today...\n more…

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Globe Newswire SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that...\n more…

Sean A. Mccarthy Sells 13,898 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock

Ticker Report CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CEO Sean A. Mccarthy sold 13,898 shares of the firm's stock in a transaction on Tuesday, August 20th. The stock was sold at an average price...\n more…

CytomX Therapeutics (NASDAQ:CTMX) Given "Neutral" Rating at HC Wainwright

Ticker Report HC Wainwright reissued their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX - Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. CTMX has been...\n more…